Alexandria Real Estate Equities (ARE) has been a hive of activity with various shares acquired by various firms such as
Empowered Funds LLC, Mitsubishi UFJ Trust & Banking Corp, and Bleakley Financial Group LLC. The company noted some underperformance in its stock but managed to secure a significant
$5 billion credit facility. The company's shares were also sought after by multiple investors like
M&G Plc and Forsta AP Fonden.
Alexandria's Q2 earnings are due, and their price target was increased to $133.00 by Evercore ISI, indicating a positive outlook. They also made headlines as they released their
2023 Corporate Responsibility Report and secured major
leases with top pharmaceutical companies for their R&D Life Science Centers. There were several instances of insider selling, and the company made moves to enhance its dividend yield. They have also announced significant partnerships, such as an exclusive one
with Lilly to expand Lilly Gateway Labs to San Diego. The company continues to be championed as a top dividend stock. Overall, the activities reflect a company active in its sector, engaging in multiple asset-management activities while retaining a commitment to corporate responsibility and innovation.
Alexandria Real Estate Equities ARE News Analytics from Wed, 27 Sep 2023 07:00:00 GMT to Sun, 21 Jul 2024 17:41:25 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -2
